Holen Sie sich die Stockscreener-App
54.17
0.08%
-0.0449
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$54.21
Offen:
$54.21
24-Stunden-Volumen:
2.90M
Relative Volume:
0.18
Marktkapitalisierung:
$110.28B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
18.29
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
-0.99%
1M Leistung:
+10.10%
6M Leistung:
+17.02%
1J Leistung:
-4.23%
1-Tages-Spanne:
$54.03
$54.35
1-Wochen-Bereich:
$53.92
$55.04
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.17 | 110.36B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,080.26 | 966.40B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.30 | 498.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
230.13 | 406.04B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.36 | 266.17B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.69 | 263.24B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Ex-Dividend Reminder: Encompass Health, Bristol Myers Squibb and Federal Realty Investment Trust - Nasdaq
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY - ts2.tech
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating - Finviz
BMY vs AMGN: Which Biotech Stock Is More Resilient Now? - Finviz
Is Bristol Myers Squibb a buy, sell, or hold in 2026? - MSN
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? - The Motley Fool
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - Finviz
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - The Motley Fool
Bristol-Myers Squibb Stock Finds a Floor as Wall Street Bets on a Late-Cycle Rebound - AD HOC NEWS
Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Inside Bristol-Myers Squibb: How a Quiet Pharma Giant Is Re?Architecting the Future of Cancer and Im - AD HOC NEWS
What does Wall Street think about Bristol-Myers Squibb Company (BMY)? - MSN
What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)? - Finviz
10 Best Affordable Healthcare Stocks to Buy Now - Insider Monkey
Bristol-Myers Squibb Stock: Defensive Pharma Giant Tests Investor Patience As Wall Street Turns Sele - AD HOC NEWS
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears - ts2.tech
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open - ts2.tech
Bristol-Myers Squibb Charts a New Strategic Course with U.S. Government Pact - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open - ts2.tech
Meyer Handelman Co. Sells 52,438 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Trust Co. of Toledo NA OH Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts - ts2.tech
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever - Finviz
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds - Seeking Alpha
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is OverIt's Not - Seeking Alpha
Bristol Myers lines up many launches for India with 'AI' speed - The Economic Times
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact - Finviz
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance UK
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025) - ts2.tech
J&J, Bristol Myers Ask High Court to Review US Drug Price Cuts - Bloomberg Law News
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield - Seeking Alpha
Bristol-Myers Squibb stock holds Buy rating at Guggenheim amid oHCM competition - Investing.com India
3 Top Value Stocks to Buy and Hold for 2026 - Morningstar
Harbour Biomed closes busy year with $1B+ BMS deal - BioWorld MedTech
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday - ts2.tech
Exchange Traded Concepts LLC Purchases 83,214 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by First Bank & Trust - MarketBeat
Bristol-Myers Squibb Secures Regulatory Truce with Landmark U.S. Pricing Deal - AD HOC NEWS
Cytokinetics set to battle Bristol Myers as FDA approves heart drug - BioPharma Dive
BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral - Finviz
FDA Approves Bristol-Myers Squibb's Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma - Finviz
FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma - Insider Monkey
Flputnam Investment Management Co. Purchases 64,133 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Bristol Myers Squibb Company Equity Right stock compares to industry benchmarksEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Leerink Partners Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
US FDA approves Cytokinetics' heart disease drug - Reuters
Nine biopharmas agree to most-favoured nation drug pricing in the US - FirstWord Pharma
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):